Minoryx Therapeutics, S.L.
Leriglitazone
Cerebral Adrenoleukodystrophy (cALD)
Countdown
328days
Phase 3 readout · ~ May 31, 2027 estimated
What's at stake
Phase 3 trial results for Leriglitazone in Cerebral Adrenoleukodystrophy (cALD) are due ~ May 31, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT05819866: Phase 3 trial, sponsor Minoryx Therapeutics, S.L., drug Leriglitazone. Primary completion date 2027-05 (estimated).”